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S U M M A R Y
Objective: To analyze clinical features and outcomes of patients with hospital-acquired (HA) and
healthcare-associated (HCA) Staphylococcus aureus bacteremia.
Methods: A retrospective cohort study was conducted from 1988 to 2007. We compared patients with
clinically signiﬁcant HA with those with HCA S. aureus bacteremia. Risk factors for 30-day all-cause
mortality were assessed using multivariable logistic regression analysis. Cox regression analysis was
used to estimate the hazard ratio (HR) for 5-year mortality with 95% conﬁdence intervals (CI).
Results: Of 1261 episodes, 735 (58.3%) were HA and 526 (41.7%) were HCA. The percentage of MRSA was
48.2% (354/735) in HA vs. 42.2% (222/526) in HCA bacteremia; p = 0.04. The percentages of HCA S. aureus
bacteremia and MRSA bacteremia did not vary throughout the study period. Mortality at 30 days was
40.2% (507/1261) and at 1 year was 63.4% (800/1261); this was comparable for HA and HCA bacteremia.
Five-year survival curves in both settings followed very similar patterns (HR 1.01, 95% CI 0.89–1.15). Risk
factors for 30-day mortality were similar, except for primary bacteremia and pre-existing heart valve
disease in the HA group.
Conclusions: HCA S. aureus bacteremia shares many similarities with HA bacteremia with respect to the
prevalence of MRSA strains, mortality rates, and risk factors for death, and should be managed similarly.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Modern healthcare constitutes a continuum of care with many
traditional inpatient services provided in outpatient settings.
Invasive procedures are performed in outpatient-based clinics,
nursing homes, and long-term care facilities. Healthcare services,
such as dialysis, chemotherapy, and antibiotic therapy are
increasingly being provided in the outpatient environment. Data
indicate that patients with healthcare-associated (HCA) infections
have a unique epidemiology. The causative pathogens and
outcomes related to these infections more closely resemble those
seen with hospital-acquired (HA) infections.1–3
Staphylococcus aureus, a major pathogen causing community-
acquired, HCA, and HA infections, is associated with signiﬁcant
morbidity and mortality rates of 15–60%.4 The epidemiology of
HCA S. aureus infections has not been fully described in the§ This article was presented in part at the 21st ECCMID/27th ICC, Milan, Italy, May
7–10, 2011.
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http://dx.doi.org/10.1016/j.ijid.2012.02.009literature. Previous studies have established that the large majority
of community-onset S. aureus infections are actually HCA.5–9
Studies in the USA have described the unique epidemiology of
community-acquired methicillin-resistant S. aureus (MRSA) com-
pared to HCA and HA MRSA infections.10
To our knowledge, no study has previously compared, in detail,
HCA and HA staphylococcal bacteremia, the main epidemiological
niches of S. aureus. Such information could help design prevention
and treatment strategies for staphylococcal infections both in the
hospital and healthcare setting.
The objectives of this study were to characterize demographics,
clinical features, and outcomes of patients with HCA and HA S.
aureus bloodstream infections.
2. Patients and methods
2.1. Study design, participants, and setting
This cohort study was performed at the Rabin Medical Center,
Beilinson Hospital, a 900-bed university-afﬁliated hospital, serving
an urban population of approximately one million as a ﬁrst-line
tertiary facility. The medical facility also serves as a referral centerses. Published by Elsevier Ltd. All rights reserved.
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and long-term facilities in the surrounding area. In addition to
general surgery, there is a burn unit, cardiothoracic and
neurosurgical departments, and active solid organ transplantation
programs. There are four intensive care units: general, cardiac,
neurosurgical, and cardiothoracic.
The study was approved by the local ethics committee. The
need for informed consent was waived given the observational
nature of the study. All data were kept anonymously.
Patients with positive blood cultures for S. aureus were
identiﬁed using the Microbiology Laboratory’s database of the
years 1988–1994 (prospective identiﬁcation of patients and
collection of data) and 1999–2007 (retrospective collection of
data). The study methods have been described previously.11–13
We included all patients in whom S. aureus was identiﬁed in at
least two separate sets of blood cultures and those who fulﬁlled
the criteria for systemic inﬂammatory response syndrome within
48 h of a positive blood culture with no other source of infection.
Repeat episodes were included if an interval of 1 year or more had
passed between episodes. Polymicrobial bacteremia was included
if S. aureus was identiﬁed in at least two separate sets of blood
cultures.
2.2. Variables
Data were extracted from the patient written and electronic
charts and the Microbiology Laboratory records. The dataset
included patient demographics and background conditions,
including functional capacity before admission, sepsis severity
measures, source of infection, number of positive blood cultures,
previous antibiotic therapy, and all antibiotics administered from
the time of blood culture letting.
The presence of catheters and foreign bodies was documented
at onset and at removal during the management of the infection.
Study years were divided into four time periods (1988–1994,
1999–2001, 2002–2004, 2005–2007), allowing for assessment of
changes over time.
2.3. Deﬁnitions
Bacteremia was considered HA when blood cultures were taken
more than 48 h after admission and HCA for patients receiving
home and/or ambulatory intravenous therapy, chemotherapy,
hemodialysis, wound care, specialized nursing care, or who had
attended a hospital clinic within the last 30 days; patients
hospitalized in an acute care hospital for 2 days within the last 90
days; and those residing in a nursing home or long-term care
facility.1 Persistent bacteremia was deﬁned as S. aureus growth
with a similar susceptibility pattern from day 7 and onwards
within 30 days of the ﬁrst positive blood culture. Relapse was
deﬁned as S. aureus growth with a similar susceptibility pattern
after day 30, within 1 year of a ﬁrst positive blood culture.
Inappropriate empirical antibiotic therapy was deﬁned when the
antibiotic(s) given for the ﬁrst 48 h after blood culture letting did
not match the in vitro susceptibilities of the S. aureus isolate. Single
covering aminoglycoside or rifampin treatment was considered
inappropriate.
2.4. Outcomes
The main outcome assessed was all-cause mortality at 30 days.
Risk factors for 30-day mortality were analyzed. In addition, we
documented microbiological failure (deﬁned as persistence or
relapse), 1-year mortality, and 5-year survival. Mortality was
ascertained for all patients through the Israeli Internal Ministry
Registry.2.5. Statistical analysis
Categorical variables were compared using the Chi-square test;
continuous variables by the t-test (presented as means with
standard deviations, SD) or the Mann–Whitney U-test (medians
with interquartile range, IQR). Variables signiﬁcantly associated
with 30-day mortality (p < 0.05) were entered into a multivariable
logistic regression analysis, forcing methicillin-resistance into the
model and entering other variables using backward stepwise
logistic regression. A few missing values for laboratory measure-
ments were imputed using multiple imputation analysis with the
fully conditional speciﬁcation method.14 Odds ratios (OR) with 95%
conﬁdence intervals (CI) are reported.
Survival was assessed using the Kaplan–Meier analysis,
comparing HA and HCA bacteremia using a log-rank test. A
univariate Cox regression analysis was used to estimate the hazard
ratio (HR) for death.
3. Results
During the study period, 1347 clinically-signiﬁcant episodes of
S. aureus bacteremia were identiﬁed. Only 86 (6.4%) were
community-acquired with no identiﬁed contact with the health-
care environment; all were caused by methicillin-susceptible S.
aureus. Of the remaining 1261 episodes, 735 (58.3%) were HA and
526 (41.7%) were HCA. The proportion of HA infections did not
decrease with time (52%, 63.1%, 56.5%, and 62.4% from the ﬁrst to
the fourth study period, respectively). The main reason for
healthcare acquisition was previous hospitalization within 90
days, documented in 62.2% (138/222) of patients with MRSA and
56.6% (172/304) of patients with methicillin-sensitive S. aureus
(MSSA) HCA bacteremia. Arrival from a nursing home or chronic
care facility was documented in 40.5% (90/222) of patients with
MRSA and 30.3% (92/304) of patients with MSSA HCA bacteremia.
Among HA bacteremia, the median length of stay before
bacteremia was 6 days (IQR 3–11) for MSSA and 13 (IQR 6–27)
for MRSA.
3.1. Underlying conditions (Table 1)
Comparisons between patients with HCA and HA bacteremia
reﬂected the differences expected between patients arriving from
chronic care facilities and hospitalized patients. Patients who
acquired the bacteremia in hospital had more devices and had a
higher rate of surgical or other invasive interventions prior to
bacteremia. Patients from the healthcare setting were more
frequently debilitated or on hemodialysis. There were no
differences in patient background conditions other than a higher
rate of congestive heart failure and underlying heart valve disease
in HA bacteremia. Previous antibiotic treatment was common in
both settings and higher in the hospital (43.8%).
3.2. Infection characteristics (Table 2)
Sources of S. aureus bacteremia were similarly distributed,
however there was a higher rate of skin/soft tissue source of
infection in the healthcare setting and unknown source of infection
(primary bacteremia) in the hospital setting. Sepsis severity
measures were similar, except for the higher baseline incidence
of renal failure with HCA bacteremia and lower albumin levels at
onset with HA bacteremia. Polymicrobial bacteremia occurred in
12.8% (161/1261) of episodes and was similar in both settings.
Acinetobacter sp were the most frequent co-pathogens in HA
bacteremia and Escherichia coli in HCA bacteremia.
The percentage of MRSA was 48.2% (354/735) in HA bacteremia
and 42.2% (222/526) in HCA bacteremia, p = 0.04. No consistent
Table 2
Infection characteristics of healthcare-associated and hospital-acquired Staphylococcus aureus bacteremia (n (%), unless otherwise indicated)
Healthcare-associated (HCA)
(n = 526)
Hospital-acquired (HA)
(n = 735)
p-Value
Source of bacteremia
Surgical wound infection 55 (10.5) 69 (9.4)
Other skin/soft tissue 87 (16.5) 83 (11.3) 0.014a
Bone/joint 40 (7.6) 31 (4.2)
Pneumonia 57 (10.8) 87 (11.8)
Endocarditis (at presentation) 23 (4.4) 32 (4.4)
Catheter-related bacteremia 63 (12.0) 109 (14.8)
Other endovascular 31 (5.9) 53 (7.2)
Other documented source 69 (13.1) 74 (10.1)
Primary/unknown source 101 (19.2) 197 (26.8) 0.002b
Polymicrobial bacteremia
Any 64 (12.2) 97 (13.2)
Gram-negativec 33 (6.3) 56 (7.6) NS
Gram-positived 23 (4.4) 23 (3.1)
Combined 6 (1.1) 18 (2.4)
Sepsis presentation
Temperature 8C, mean (SD), n 38.1 (1.3), 516 38.4 (1.1), 711 0.001
Septic shock at onset 75 (14.3) 79 (10.7) NS
Leukocytes  109/l, median (IQR), n 12.5 (8.6–17.9), 522 12.1 (8–1605), 717 NS
Thrombocytes  109/l, median (IQR), n 212 (140–320), 505 214.5 (141–310), 690 NS
Urea mg/dl, median (IQR), n 57 (31.5–99.5), 508 49.5 (29–87.5), 704 0.033
Creatinine mg/dl, median (IQR), n 1.3 (0.9–2.3), 492 1.1 (0.8–1.7), 690 <0.001
Albumin g/dl, median (IQR), n 2.9 (2.5–3.3), 453 2.7 (2.3–3.2), 648 0.001
Glucose mg/dl, median (IQR), n 130.5 (101–194), 398 129 (100–190), 589 NS
SD, standard deviation; IQR, interquartile range; NS, not signiﬁcant.
a p-Value refers to any skin/soft tissue source of infection (including surgical wound infection) vs. all others.
b p-Value refers to the comparison of primary bacteremia vs. all others.
c Acinetobacter sp most common for HA bacteremia, followed by Pseudomonas sp and Klebsiella sp. Pseudomonas sp and Escherichia coli most common in HCA bacteremia.
d Enterococcus sp most common in both HA and HCA bacteremia.
Table 1
Characteristics of patients with healthcare-associated and hospital-acquired Staphylococcus aureus bacteremia (n (%), unless otherwise indicated)
Healthcare-associated (HCA)
(n = 526)
Hospital-acquired
(HA) (n = 735)
p-Value
Demographics
Age (years), mean (SD) 71.9 (15.4) 68 (15.7) NS
Female 222 (42.2) 298 (40.5) NS
Bedridden at admission 185 (35.2) 203 (27.6) 0.028
Dementia 118 (22.4) 84 (11.4) <0.001
Decubitus ulcer 83 (15.8) 101 (13.7) NS
Underlying conditions
Charlson comorbidity index, median (IQR) 3 (2–4) 3 (1–4) NS
Diabetes mellitus 190 (36.1) 262 (35.6) NS
Malignancy 132 (25.1) 190 (25.9) NS
Chronic pulmonary disease 50 (9.5) 99 (13.5) NS
Chronic renal failure 165 (31.4) 176 (23.9) 0.004
Hemodialysis 55 (10.5) 36 (4.9) <0.001
Chronic heart failure 69 (13.1) 158 (21.5) <0.001
Pre-existing valvular heart disease 55 (10.5) 112 (15.2) 0.014
Cerebrovascular event 96 (18.3) 124 (16.9) NS
Devices at onset of infection
Central catheter 79 (15.0) 156 (21.2) 0.005
Urine catheter 164 (31.2) 330 (44.9) <0.001
Foreign bodya 55 (10.5) 80 (10.9) NS
Risk factors within 30 days prior to bacteremia
Surgery 93 (17.7) 232 (31.6) <0.001
Other invasive proceduresb 85 (16.2) 264 (35.9) <0.001
Previous antibiotics (30 days) 163 (31.0) 322 (43.8) <0.001
Previous b-lactam 89 (16.9) 263 (35.8) <0.001
Previous quinolone 185 (35.2) 232 (31.6) NS
Corticosteroid treatment (last 30 days) 47 (8.9) 133 (18.1) <0.001
Chemotherapy 51 (9.7) 74 (10.1) NS
SD, standard deviation; IQR, interquartile range; NS, not signiﬁcant.
a Including prosthetic valve, pacemaker, prosthetic joint, vascular implant, or cerebral shunt.
b Including catheterization, invasive radiology, pleural or peritoneal centesis, drainage, debridement, or other interventions performed outside the operation room.
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the four study periods (Figure 1). MRSA rates in both settings were
similar during the last study period (122/244, 50% vs. 71/147,
48.3%, respectively, p = 0.74).The proportion of HA MRSA bacteremia of all MRSA bacteremia
did not decrease during the study period (49.6%, 65.5%, 66.1%, and
63.2% from the ﬁrst to the fourth study period, respectively). All
isolates were sensitive to vancomycin (minimum inhibitory
Figure 1. Methicillin-resistant Staphylococcus aureus (MRSA) percentage and inappropriate empirical antibiotic treatment throughout the study period. Statistically
signiﬁcant differences (p < 0.05) between healthcare-associated (HCA) and hospital-acquired (HA) bacteremia for MRSA % and inappropriate empirical antibiotic treatment
only in the third study period.
J. Bishara et al. / International Journal of Infectious Diseases 16 (2012) e457–e463e460concentration (MIC) 2; data not shown). HCA MRSA isolates were
more frequently susceptible to clindamycin, gentamicin, and
oﬂoxacin and less frequently to co-trimoxazole, however the
differences were small and without clinical signiﬁcance for
empirical treatment (Figure 2).
3.3. Management and outcomes (Table 3)
The overall rate of appropriate empirical antibiotic treatment
was similar for HCA and HA infections. Changes in empirical
coverage followed the rates of MRSA during the study periods
(Figure 1). Rates of appropriate empirical treatment for MRSA
were similar overall and in all study periods except for the last
period (2005–2007), where appropriate coverage was achieved
signiﬁcantly more frequently in hospital (53/122, 43.4% of HA
bacteremia vs. 16/71, 22.5% of HCA bacteremia treated empiri-
cally, p = 0.003). Rates of transthoracic echocardiography (TTE)
and transesophageal echocardiography (TEE) were similar for
HCA and HA patients, as were surgical intervention rates,
performed as part of infection management, catheter extraction,
and foreign body removal (Table 3).
Persistence of bacteremia was more frequently documented
with HCA bacteremia, leading to a higher rate of bacteriological
failure. Central catheter and pre-existing heart valve disease were
associated with persistence of bacteremia and bacteriological
failure and were more frequent in the HA setting. Patients with HAFigure 2. In vitro resistance of methicillin-resistant Staphylococcus aureus (MRSA)
healthcare-associated (HCA) and hospital-acquired (HA) bloodstream isolates to
clindamycin (CLN), co-trimoxazole (COTR), fusidic acid (FUCID), rifampin (RFM),
gentamicin (GENT), oﬂoxacin (OFLO), and tetracycline (TETRA); *p < 0.05.bacteremia stayed longer in hospital following bacteremia, with a
median difference of 2 days (Table 3). Mortality at 30 days was
40.2% (507/1261) and at 1 year was 63.4% (800/1261); mortality
was similar for HA and HCA bacteremia. Five-year survival curves
in both settings followed very comparable patterns (HR 1.01, 95%
CI 0.89–1.15, Figure 3). Risk factors for death on univariate and
multivariate analysis are shown in Table 4. Most independent risk
factors were common in both settings, including age, female sex,
poor functional capacity, use of corticosteroids before infection,
septic shock at presentation, lower albumin and thrombocyte
count, and higher urea levels. Inappropriate empirical antibiotic
treatment was associated with a similar increase in mortality in
both settings, which was statistically signiﬁcant with HA bacter-
emia. The only differences in the adjusted analysis were that pre-
existing valvular heart disease and primary bacteremia were risk
factors for death in HA bacteremia. MRSA was not a signiﬁcant risk
factor for death in either cohort.
4. Discussion
The characteristics and outcomes of HCA and HA S. aureus
bacteremia were very similar in our center and had been so for a
long period of time. Differences in baseline patient characteristics
mainly reﬂected the site of acquisition of the infection. Sepsis
presentation and sources of infection were mostly alike. All-cause
mortality was high (40.2% at 30 days and 63.4% at 1 year) and
remarkably similar in HA and HCA bacteremia. Five-year survival
rates were similar as well (HR 1.01, 95% CI 0.89–1.15). The
proportion of MRSA in the hospital and healthcare settings was
similar during the last study period (50% vs. 48.3%, respectively)
and slightly higher with HA bacteremia (48.2% vs. 42.2%,
respectively), however the magnitude of the difference was
without epidemiological consequences or clinical signiﬁcance
for empirical treatment. The proportion of HA acquisition was
stable throughout the study period and in MRSA bacteremia.
Previous studies comparing HCA and HA infections have
reported similar mortality rates in both settings with any
bacteremia,2,15,16 Gram-negative bacteremia,17 pneumonia,18
and S. aureus bacteremia.6 Friedman et al. reported higher
short-term mortality rates in HA bacteremia compared to HCA
bacteremia, but similar long-term mortality.1 There are probably
common underlying reasons leading to the dismal long-term
prognosis following bacteremia, relating to the risk factors that led
to the bacteremia and to the effects of a severe infection, mainly in
elderly patients.19 Independent risk factors for death were similar
Table 3
Management and outcomes of healthcare-associated and hospital-acquired Staphylococcus aureus bacteremia
Healthcare-associated (HCA)
(n = 526)
Hospital-acquired (HA)
(n = 735)
p-Value
Antibiotic treatment
Inappropriate empirical therapy 189/526 (35.9) 288/735 (39.2) NS
Inappropriate empirical for MSSA 34/304 (11.2) 54/381 (14.2) NS
Empirical vancomycin for MSSA 62/304 (20.4) 85/381 (22.3) NS
Inappropriate empirical for MRSA 155/222 (69.8) 234/354 (66.1) NS
Other management
Central catheter removal documenteda 30/71 (42.3) 43/138 (31.2) NS
Removal of foreign bodyb 13/55 (23.6) 12/80 (15) NS
Drainage/debridement 66/381 (17.3) 82/577 (14.2) NS
Any surgical intervention 87/493 (17.6) 106/697 (15.2) NS
Vasopressor therapy 142/526 (27.0) 219/734 (29.8) NS
Outcome
Persistence of bacteremia 7 daysc 56/410 (13.7) 51/596 (8.6) 0.01
Relapsed 21/329 (6.4) 16/425 (3.8) NS
Microbiological failure (persistence 5 days or relapse)c 68/329 (20.7) 63/425 (14.8) 0.036
Length of stay (days), all patients, median (IQR) 10 (4–19) 12 (6–24) 0.001
Length of stay (days), patients discharged alive, median (IQR) 12 (6–20) 14 (8–26) <0.001
30-day all-cause mortality 197/526 (37.5) 310/735 (42.2) NS
1 year 330/526 (62.7) 470/735 (63.9) NS
MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus; NS, not signiﬁcant; IQR, interquartile range.
a Assessed for patients with central venous catheter at onset of infection.
b Assessed for patients with foreign body at onset of infection (see Table 1).
c Assessed for patients alive at day 7.
d Assessed for patients alive at 1 year.
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reﬂecting the prevalence of risk factors in the two populations.
Inappropriate empirical antibiotic treatment was associated with
death, mainly on account of inappropriate empirical treatment of
MRSA,12 which was signiﬁcantly more frequent than inappropriate
treatment for MSSA.
Similar rates of MRSA have been reported in HCA and HA
infections in studies conducted in the USA.1,2,6,18 Son et al. reportedFigure 3. Kaplan–Meier 5-year survival plot. 0 (blue line): healthcare-associated Stap
bacteremia patients. There were no losses to follow-up. Censored cases had not reachea higher prevalence of MRSA with HA compared to HCA bacteremia
in Korean patients.16 This may reﬂect true differences in
epidemiology, different deﬁnitions of healthcare acquisition, or
different patient populations within the HCA category. In our
study, similar MRSA rates were to be expected given that most
patients in the HCA category had previously been hospitalized.
Recently, a decrease in HCA-MRSA infection incidence rates has
been reported following infection control interventions focusinghylococcus aureus bacteremia patients; 1 (green line): hospital-acquired S. aureus
d the 5-year end of follow-up. Log rank test p = 0.846.
Table 4
Risk factors for 30-day all-cause mortality in healthcare-associated and hospital-acquired Staphylococcus aureus bacteremiaa
Healthcare-associated (HCA) Hospital-acquired (HA)
Alive (n=311) Dead (n=189) p-Value Multivariate, OR (95% CI),
p-value
Alive (n=411) Dead (n=297) p-Value Multivariate, OR (95% CI),
p-value
Age years, mean (SD) 68.3 (16.6) 77.6 (12) <0.001 1.03 (1.01–1.05), 0.002 64.8 (16.5) 74 (12.8) <0.001 1.03 (1.02–1.05), <0.001
Female 117 (37.6) 96 (50.8) 0.004 1.59 (1.00–2.51), 0.049 154 (37.5) 134 (45.1) 0.037 1.47 (1.02–2.11), 0.036
Bedridden at admission 72 (23.2) 112 (59.3) <0.001 2.60 (1.55–4.38), <0.001 81 (19.7) 115 (38.7) <0.001 1.51 (1.00–2.28), 0.048
Previous CVAb 38 (12.2) 51 (27.0) <0.001 70 (17.0) 51 (17.2) NS
Pre-existing valvular heart disease 34 (10.9) 16 (8.5) NS 44 (10.7) 62 (20.9) <0.001 1.83 (1.10–3.04), 0.020
Mechanical ventilationc 5 (1.6) 16 (8.5) <0.001 3.05 (0.94–9.86), NS 69 (16.8) 84 (28.3) <0.001 Excluded from the model
Recent surgery 74 (23.8) 17 (9.0) <0.001 0.54 (0.27–1.07), NS 135 (32.8) 90 (30.3) NS
Previous antibiotic treatment 92 (29.6) 57 (30.2) NS 158 (38.4) 147 (49.5) 0.003 Excluded from the model
Previous steroid treatment 21 (6.8) 25 (13.2) 0.015 2.70 (2.30–5.63), 0.008 64 (15.6) 67 (22.6) 0.018 1.93 (1.23–3.03), 0.004
Chronic renal failureb 78 (25.1) 72 (38.1) 0.002 65 (15.8) 102 (34.3) <0.001
Skin/soft tissue source of infection 92 (29.6) 41 (21.7) NS 102 (24.8) 43 (14.5) 0.001 Excluded from the model
Primary bacteremia 52 (16.7) 44 (23.3) NS 84 (20.4) 95 (32.0) <0.001 1.86 (1.23–2.81), 0.003
MRSA 116 (37.3) 86 (45.5) NS 175 (42.6) 163 (54.9) 0.001 Excluded from the model
Shock at onset 20 (6.4) 51 (27.0) <0.001 4.23 (2.23–8.04), <0.001 19 (4.6) 56 (18.9) <0.001 3.45 (1.86–6.38), <0.001
Inappropriate empirical antibiotic treatment 98 (31.5) 85 (45.0) 0.004 1.52 (0.95–2.44), NS 141 (34.3) 135 (45.5) 0.003 1.51 (1.04–2.20), 0.029
Leukocytes109/l, median (IQR) 12 (8.3–7.4) 13.3 (8.6–19.5) NS 11.6 (7.7–15.6) 13.4 (8.7–17.9) 0.004 Excluded from the model
Thrombocytes109/l, median (IQR) 230 (160–331) 180 (110–279) <0.001 0.997 (0.995–0.998), <0.001 231 (161–335) 193 (113–288) <0.001 0.997 (0.996–0.998), <0.001
Urea mg/dl, median (IQR)d 43 (26–79) 76 (46–125) <0.001 1.006 (1.002–1.01), 0.002 36 (22–61) 70 (41–125) <0.001 1.008 (1.004–1.011), <0.001
Albumin g/dl, median (IQR) 3.1 (2.7–3.5) 2.7 (2.2–3) <0.001 0.37 (0.25–0.55), <0.001 3 (2.5–3.4) 2.6 (2.2–3) <0.001 0.46 (0.35–0.63), <0.001
Hosmer and Lemeshow test 0.564 0.32
AUC <0.001 0.84 (0.81–0.88) <0.001 0.81 (0.77–0.84)
OR, odds ratio; 95% CI, 95% conﬁdence interval; SD, standard deviation; NS, not signiﬁcant; IQR, interquartile range; CVA, cerebrovascular accident; AUC, area under the curve.
a Analysis performed per patient, using patient’s ﬁrst episode of S. aureus bacteremia. All variables in Tables 1 and 2 assessed; only variables signiﬁcantly associated with death on univariate analysis are shown.
b Not used in multivariable analysis due to correlation with other variables.
c Urine catheter was similarly associated with death in both settings, but highly correlated with mechanical ventilation.
d Creatinine similarly associated with death in both settings.
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of 11.2% in HA-MRSA bacteremia incidence rates and a 6.6%
decrease in HCA community-onset bacteremia between 2005 and
2008 in the USA.5 The Health Protection Agency in the UK reported
that HA-MRSA bacteremia rates declined by 65% between 2005
and 2009.20 No change was noted during this time period in the
number of MRSA bacteremia reported in non-acute care healthcare
facilities. In 2008, the European Antimicrobial Resistance Surveil-
lance System (EARSS) reported for the ﬁrst time a decrease in
MRSA percentages in hospital-associated bacteremia in most
European countries.21 No decrease in MRSA rates throughout the
study period or in the hospital settings was observed. Indeed, in
Israel there are no national initiatives to combat MRSA, and in our
hospital there was no screening or isolation policy for MRSA
carriers during the study period given the endemicity of MRSA in
the hospital.
Our study spans a long period and we cannot be sure that the
same deﬁnitions were applied for the clinical signiﬁcance of S.
aureus bloodstream isolates and other variables throughout this
period. The proportion of community-acquired S. aureus bacter-
emia was low compared to studies applying similar criteria for
hospital and healthcare acquisition of all S. aureus bacteremia.22–
25 Differences could lie in the deﬁnitions of healthcare acquisition
or truly variable epidemiology. An advantage of our study was that
a single electronic system recorded all hospitalizations and
procedures in the community, thus enabling us to fully capture
the data needed to deﬁne healthcare acquisition. The main
difference is probably that our center is a primary and tertiary care
hospital located in a region with many nursing homes and caring
for a relatively elderly population. We could not compute HA and
HCA S. aureus bacteremia incidence rates with the available data.
Data on the performance of TTE and TEE were probably
incomplete due to poor documentation of these procedures and
the retrospective study design. Thus, our estimate of endocarditis
might be too low.
In summary, HCA S. aureus bacteremia shares many similarities
with HA bacteremia, especially with respect to the prevalence of
MRSA and mortality rates. Appropriate empirical treatment for
MRSA decreases mortality,19 and thus empirical treatment should
target MRSA similarly in HCA and HA infections in patients at a
high risk for MRSA.8,26 Infections should be similarly managed
given the similar and grave prognosis. Our epidemiology calls for
interventions to reduce MRSA rates in both the hospital and
healthcare setting.
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